Reproducibility of fifteen urinary estrogens and estrogen metabolites over a 2- to 3-year period in premenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 11, 2009, Pages 2860-2868

  Eliassen, A Heather ^a   Ziegler, Regina G ^c   Rosner, Bernard ^a,b   Veenstra, Timothy D ^d   Roman, John M ^d   Xu, Xia ^d   Hankinson, Susan E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16 OXOESTRADIOL; 16ALPHA HYDROXYESTRONE; 17 EPIESTRIOL; 2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 2 HYDROXYESTRONE 3 METHYLETHER; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRONE; 4 METHOXYESTRADIOL; 4 METHOXYESTRONE; CATECHOL DERIVATIVE; EPIESTRIOL; ESTRADIOL; ESTRIOL; ESTROGEN DERIVATIVE; ESTRONE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROXYLATION; LUTEAL PHASE; METABOLITE; PREMENOPAUSE; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS;

AGED; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; PREMENOPAUSE; PROGNOSIS; QUESTIONNAIRES; RISK FACTORS; TANDEM MASS SPECTROMETRY;

EID: 72749125601     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0591     Document Type: Article

References (62)

1. Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008;630:148-65.
2. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
3. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65.
4. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12:1071-82.
5. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 2006;24:1823-30.
6. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79-85.
7. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
8. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000;9:575-9.
9. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994;140:518-25.
10. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 1997;75:1075-9.
11. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125:791-9.
12. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-8.
13. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406-15.
14. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
15. Lottering ML, Haag M, Seegers JC. Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 1992;52:5926-32.
16. Schutze N, Vollmer G, Knuppen R. Catecholestrogens are agonists of estrogen receptor dependent gene expression in MCF-7 cells. J Steroid Biochem Mol Biol 1994;48:453-61.
17. Schutze N, Vollmer G, Tiemann I, Geiger M, Knuppen R. Catecholestrogens are MCF-7 cell estrogen receptor agonists. J Steroid Biochem Mol Biol 1993;46:781-9.
18. Jefcoate CR, Liehr JG, Santen RJ, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 2000:95-112.
19. Yue W, Santen RJ, Wang JP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86.
20. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
21. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci U S A 1985;82:6295-9.
22. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9.
23. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16α-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998;27:294-9.
24. Zheng W, Dunning L, Jin F, Holtzman J. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomark Prev, 6: 505-509, 1997.
25. Cancer Epidemiol Biomarkers Prev 1998;7:85-6, Correspondence re: G.C. Kabat et al.
26. Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/ 16α-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:1067-72.
27. Schneider J, Kinne D, Fracchia A, et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci U S A 1982;79:3047-51.
28. Adlercreutz H, Fotsis T, Hockerstedt K, et al. Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J Steroid Biochem 1989;34:527-30.
29. Fowke JH, Qi D, Bradlow HL, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus posttreatment collection. Steroids 2003;68:65-72.
30. Kabat GC, O'Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology 2006;17:80-8.
31. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250-5.
32. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausalwomen. Epidemiology 2000;11:635-40.
33. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2005;14:2137-42.
34. Cauley JA, Zmuda JM, Danielson ME, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology 2003;14:740-4.
35. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16α-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-35.
36. Xu X, Veenstra TD, Fox SD, et al. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 2005;77:6646-54.
37. Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG. A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev 2008;17:3411-8.
38. Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN,Hankinson SE. Reproducibility of plasmasteroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2-3 year period.Cancer Epidemiol Biomarkers Prev 2006;15:972-8.
39. Xu X, Keefer LK, Ziegler RG, Veenstra TD. A liquid chromatographymass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. Nat Protoc 2007;2:1350-5.
40. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
41. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983;25:165-72.
42. Rosner B, Glynn RJ. Interval estimation for rank correlation coefficients based on the probit transformation with extension to measurement error correction of correlated ranked data. Stat Med 2007; 26:633-46.
43. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995;4:649-54.
44. Shekelle RB, Shryock AM, Paul O, et al. Diet, serum cholesterol, and death from coronary heart disease. The Western Electric study. N Engl J Med 1981;304:65-70.
45. Rosner B, Hennekens CH, Kass EH, Miall WE. Age-specific correlation analysis of longitudinal blood pressure data. Am J Epidemiol 1977;106:306-13.
46. Gordon T, Shurtleff D. The Framingham Study: an epidemiologic investigation of cardiovascular disease. Section 29: Means at each examination and inter-examination variation of specified characteristics: Framingham Study Exam 1 to Exam 10. 1973: DHEW Pub No. (NIH) 74-478.
47. Van Aswegen CH, Purdy RH, Wittliff JL. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 1989;32:485-92.
48. Anstead GM, Carlson KE, Katzenellenbogen JA. The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 1997;62:268-303.
49. Barnea ER, MacLusky NJ, Naftolin F. Kinetics of catechol estrogenestrogen receptor dissociation: a possible factor underlying differences in catechol estrogen biological activity. Steroids 1983;41:643-56.
50. Miyairi S, Ichikawa T, Nambara T. Structure of the adduct of 16α-hydroxyestrone with a primary amine: evidence for the Heyns rearrangement of steroidal D-ring α-hydroxyimines. Steroids 1991;56:361-6.
51. Bucala R, Fishman J, Cerami A. Formation of covalent adducts between cortisol and 16α-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus. Proc Natl Acad Sci U S A 1982;79:3320-4.
52. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci US A 1988;85:7831-5.
53. Lustig RH, Mobbs CV, Pfaff DW, Fishman J. Temporal actions of 16α-hydroxyestrone in the rat: comparisons of lordosis dynamics with other estrogen metabolites and between sexes. J Steroid Biochem 1989;33:417-21.
54. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006.
55. Gupta M, McDougal A, Safe S. Estrogenic and antiestrogenic activities of 16α- and 2-hydroxy metabolites of 17β-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol 1998;67:413-9.
56. Schneider J, Huh MM, Bradlow HL, Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 1984;259:4840-5.
57. Vandewalle B, Lefebvre J. Opposite effects of estrogen and catecholestrogen on hormone-sensitive breast cancer cell growth and differentiation. Mol Cell Endocrinol 1989;61:239-46.
58. Yue TL, Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 1997;51:951-62.
59. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 2001;127:405-10.
60. Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci 2003;72:877-83.
61. Liu ZJ, Zhu BT. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptorpositive human breast cancer cells. J Steroid Biochem Mol Biol 2004;88:265-75.
62. Fukui M, Zhu BT. Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells. Mol Carcinog 2009;48:66-78.